Paul Brousse Hospital Reports Findings in Personalized Medicine (Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant che motherapy in patients with pancreatic ductal adenocarcinoma)
Paul Brousse医院报告了个性化医学的发现（AI辅助转录组信号的开发和验证，以个性化辅助治疗胰腺导管腺癌患者）
Paul Brousse Hospital Reports Findings in Personalized Medicine (Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant che motherapy in patients with pancreatic ductal adenocarcinoma)
Paul Brousse医院报告了个性化医学的发现（AI辅助转录组信号的开发和验证，以个性化辅助治疗胰腺导管腺癌患者）
By a News Reporter-Staff News Editor at Robotics & Machine Learning Daily News Daily News – New research on Drugs and Therapies - Personalized Medicine is the subject of a report. According to news reporting ou t of Villejuif, France, by NewsRx editors, research stated, “After surgical rese ction of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly tre ated with adjuvant chemotherapy, commonly consisting of gemcitabine-based regime ns or the modified FOLFIRINOX regimen (mFFX). While mFFX has been shown to be mo re effective than gemcitabine-based regimens, it is also associated with higher toxicity.”
Key words
Villejuif/France/Europe/Adenocarcinom a/Adjuvant Chemotherapy/Antimetabolites/Antineoplastics/Antivirals/Cancer/Chemotherapy/Clinical Trials and Studies/Combined Modality Therapy/Cyborgs/D rugs and Therapies/Emerging Technologies/Gastroenterology/Gemcitabine Therapy/Health and Medicine/Immunosuppressive Agents/Machine Learning/Oncology/Pan creas/Personalized Medicine/Personalized Therapy/Pharmaceuticals/Pre-Trial R esearch/Radiation-Sensitizing Agents
NETL
NSTL